Nom du produit:Isoquinoline, 4-(3-bromophenyl)-6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-, (4S)-

IUPAC Name:(4S)-4-(3-bromophenyl)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinoline

CAS:1870821-29-6
Formule moléculaire:C16H14BrCl2N
Pureté:95%+
Numéro de catalogue:CM429816
Poids moléculaire:371.1

Unité d'emballage Stock disponible Prix($) Quantité
CM429816-100mg in stock ŹůǤ
CM429816-250mg in stock ůŗNJ
CM429816-1g in stock ǤŹǤ

Pour une utilisation en R&D uniquement..

Formulaire de demande

   refresh    

Détails du produit

N° CAS:1870821-29-6
Formule moléculaire:C16H14BrCl2N
Point de fusion:-
Code SMILES:CN1C[C@@H](C2=CC(Br)=CC=C2)C2=C(C1)C(Cl)=CC(Cl)=C2
Densité:
Numéro de catalogue:CM429816
Poids moléculaire:371.1
Point d'ébullition:
N° Mdl:MFCD27939616
Stockage:

Category Infos

Tetrahydroisoquinolines
Tetrahydroisoquinoline is an organic compound with the chemical formula C9H11N. It is classified as a secondary amine, obtained from isoquinoline by hydrogenation. The tetrahydroisoquinoline moiety forms the backbone of several natural, synthetic and semi-synthetic drugs approved for the treatment of cancer, pain, gout and various neurodegenerative diseases.

Column Infos

Tenapanor
FDA has approved XPHOZAH (tenapanor), the first and only phosphate absorption inhibitor, indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

XPHOZAH, with its unique blocking mechanism of action, acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3), reducing phosphate absorption through the paracellular pathway, the primary pathway of phosphate absorption.